Boehringer Ingelheim (Canada) Ltd./Ltée.
Boehringer Ingelheim (Canada) Ltd./Ltée., a subsidiary of the global pharmaceutical giant Boehringer Ingelheim, is headquartered in Canada and operates extensively across the country. Founded in 1885, the company has established itself as a leader in the pharmaceutical industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim offers a diverse range of core products and services, including prescription medications and vaccines that address critical health challenges. The company is renowned for its research-driven approach, which has led to significant advancements in therapeutic areas such as respiratory diseases, oncology, and diabetes care. Boehringer Ingelheim's strong market position is underscored by its dedication to improving patient outcomes and its notable achievements in developing unique therapies that enhance quality of life. As a trusted name in healthcare, the company continues to make impactful contributions to both human and animal health sectors.
DitchCarbon Score
How does Boehringer Ingelheim (Canada) Ltd./Ltée.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim (Canada) Ltd./Ltée.'s score of 13 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim (Canada) Ltd./Ltée.'s reported carbon emissions
Boehringer Ingelheim (Canada) Ltd./Ltée. currently does not have available carbon emissions data for the most recent year, nor are there specific reduction targets or initiatives outlined in their climate commitments. Without concrete figures or defined goals, it is challenging to assess their current impact on carbon emissions or their strategic approach to climate change. However, the company is likely to be engaged in broader industry efforts to address climate change, which typically include commitments to reduce greenhouse gas emissions across various scopes. As the pharmaceutical industry increasingly prioritises sustainability, Boehringer Ingelheim may align with these trends in future reporting.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim (Canada) Ltd./Ltée. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
